Last reviewed · How we verify
NCT03080480
Pioglitazone Therapy for Chronic Granulomatous Disease
Terminated
Phase 1, PHASE2
Last updated 22 October 2019
What this trial tests
Phase 1, PHASE2 trial testing Pioglitazone in Chronic Granulomatous Disease in 3 participants. Terminated before completion.
Timeline
1 September 2017
Primary endpoint
20 October 2019
20 October 2019
20 October 2019
Quick facts
| Lead sponsor | Children's Hospital of Fudan University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 1 September 2017 |
| Primary completion | 20 October 2019 |
| Estimated completion | 20 October 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Pioglitazone (pioglitazone) — full drug profile →
Conditions studied
- Chronic Granulomatous Disease — all drugs for Chronic Granulomatous Disease →
Sponsor
Children's Hospital of Fudan University
Who can join
Adults 1 Month to 18, any sex, with Chronic Granulomatous Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this proposed research is to investigate the efficacy and safety of the therapy with pioglitazone for chronic granulomatous disease (CGD) patients severe infection.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.
Cheng HS, Tan WR, Low ZS, Marvalim C, et al · · 2019 · cited 196× · PMID 31614690 · DOI 10.3390/ijms20205055 -
Raising the 'Good' Oxidants for Immune Protection.
Dumas A, Knaus UG. · · 2021 · cited 28× · PMID 34149739 · DOI 10.3389/fimmu.2021.698042 -
Nuclear receptors in health and disease: signaling pathways, biological functions and pharmaceutical interventions.
Jin P, Duan X, Huang Z, Dong Y, et al · · 2025 · cited 21× · PMID 40717128 · DOI 10.1038/s41392-025-02270-3 -
Thymosin β4 promotes autophagy and repair via HIF-1α stabilization in chronic granulomatous disease.
Renga G, Oikonomou V, Moretti S, Stincardini C, et al · · 2019 · cited 13× · PMID 31719116 · DOI 10.26508/lsa.201900432 -
Does Pioglitazone Lead to Neutrophil Extracellular Traps Formation in Chronic Granulomatous Disease Patients?
Hule GP, Bargir UA, Kulkarni M, Kambli P, et al · · 2019 · cited 12× · PMID 31428088 · DOI 10.3389/fimmu.2019.01739
Verify or expand the search:
- PubMed search for NCT03080480
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pioglitazone
Trials testing the same drug.
- NCT07444424 — A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants · Phase 1 · recruiting
- NCT06657209 — Normal-weight Diabetes: Adipocyte-directed Therapy with Pioglitazone or Tirzepatide · Phase 4 · not yet recruiting
- NCT06246799 — Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes · Phase 3 · recruiting
- NCT05753657 — A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients · EARLY_PHASE1 · recruiting
- NCT05305287 — Quantifying Hepatic Mitochondrial Fluxes in Humans · Phase 4 · recruiting
Other recruiting trials for Chronic Granulomatous Disease
Currently open trials in the same condition.
- NCT07284641 — Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifest · Phase 2 · recruiting
- NCT05600907 — Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD) · EARLY_PHASE1 · active not recruiting
- NCT05189925 — NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD) · Phase 1 · recruiting
- NCT05463133 — Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan · Phase 1, PHASE2 · recruiting
- NCT03910452 — Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With P · EARLY_PHASE1 · active not recruiting
Other Children's Hospital of Fudan University trials
Trials by the same sponsor.
- NCT04955821 — Early Identification of Pathogens in Children With Respiratory Tract Infection by Mechanical Ventilation Using mNGS · not yet recruiting
- NCT05862688 — A Cohort Study on Anti-microbial Stewardship in PICU · not yet recruiting
- NCT05595239 — Blood Purification in Septic Children · NA · not yet recruiting
- NCT07325903 — Research of Integrated Traditional Chinese and Western Medicine on Precocious Puberty · EARLY_PHASE1 · not yet recruiting
- NCT07141615 — Clinical Observation of Qingwei Huazhuo Decoction (Product: Jinsaiyu) in Improving Children With Precocious Puberty of P · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03080480 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Children's Hospital of Fudan University
- Last refreshed: 22 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03080480.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing